Paul Cacciatore (@libbyshope) header
Paul Cacciatore (@libbyshope) profile picture

Founder of Libby's H*O*P*E* (*Helping *Ovarian Cancer Survivors *Persevere Through *Education)

Los Angeles
Joined February 2009
Photo by Paul Cacciatore (@libbyshope)Photo by Paul Cacciatore (@libbyshope)
Astros fan in remission from ovarian cancer attends home-opener. Last April, Janie Morris learned she had stage 3 ovarian cancer. Doctors discovered it on Morris' birthday. khou.com/article/sports/astr…
1
Stable Disease w/Tumor Shrinkage Reported in Subject 2 Following Single IP Dose of NK100 (allogeneic donor-derived natural killer (NK) cell cancer immunotherapy). ir.fatetherapeutics.com/news…
Only Certain Gynecologic Malignancies Benefit from Immunotherapy. #SGO2018 curetoday.com/articles/only-…
Women with Recurrent Ovarian Cancer Should Be Screened for Various Biomarkers. curetoday.com/articles/women…
PARP-7 Amplification Mutations Linked to Prolonged Survival in Ovarian Cancer. #SGO2018 cancernetwork.com/sgo/parp-7…
Pembrolizumab (Keytruda) + pegylated liposomal doxorubicin (PLD) produced a RR of 19% & a CBR of 43% in pts w/ recur plat-resist ovarian cancer. #SGO2018 medpagetoday.com/meetingcove…
Chlamydia Infection is Associated With Increased Risk of Ovarian Cancer. #AACR2018 aacr.org/Newsroom/Pages/News…
Repurposing Existing FDA-Approved (HDAC) Inhibitors May Provide New Treatment Approach for ARID1A-mutated ovcrs like ovarian clear cell cancer. wistar.org/news/press-releas…
Promise Seen With Frontline Pembrolizumab + Chemo in Ovarian Cancer. #SGO2018 targetedonc.com/news/promise…
Safety Analysis Favors Olaparib in Meta-Analysis Comparing PARP Inhibitors in Ovarian Cancer. #SGO2018 targetedonc.com/conference/s…
Early Biomarkers Found for Patients Requiring Dose Reduction With Niraparib in Ovarian Cancer. #SGO2018 targetedonc.com/conference/s…
Higher Toxicity With Checkpoint Inhibitor Treatment Found in Study of Recurrent Ovarian Cancer. #SGO2018 targetedonc.com/conference/s…
Predicting Response to PARP Inhibitor Therapy in Ovarian Cancer. #SGO2018 targetedonc.com/conference/s…